Venetoclax (VEN)+Azacytidine (AZA) Followed by Modified BUCY Conditioning Regimen for High Risk or Refractory/Relapsed Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT)
The purpose of this prospective, open-label, single-center study is to evaluate the efficacy and safety of VEN-AZA (venetoclax and azacytidine) followed by modified BUCY (busulfan and cyclophosphamide) as conditioning regimen for high-risk or relapsed/refractory acute lymphoblastic leukemia (ALL) undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT).
• Age 14 to 65 years;
• Diagnosis of high-risk or relapsed/refractory acute lymphoblastic leukemia at the time of transplant.
• Must need a bone marrow transplant;
• Must have the ability to observe the efficacy and events;
• Patient must have ability to understand and willingness to provide written informed consent prior to participation in the study and any related procedures being performed.